ORKA - Latest News
Oruka Therapeutics, Inc. (ORKA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.37B. Beta to the broader market is -0.25.
The article list below shows the most recent ORKA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ORKA Headlines
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com - May 13, 2026
ORKA-001 EVERLAST-A 16-week data showed 63.
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
fool.com - May 13, 2026
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
prnewswire.com - May 6, 2026
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif. , May 6, 2
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing
defenseworld.net - Apr 29, 2026
Oruka Therapeutics (NASDAQ: ORKA) reported 16-week interim results from EVERLAST-A, a double-blind, placebo-controlled phase II study evaluating ORKA-
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
globenewswire.com - Apr 28, 2026
MENLO PARK, Calif. , April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc.
How News Affects ORKA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ORKA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ORKA news questions
- What is the latest ORKA news headline?
- The most recent ORKA headline (May 13, 2026) is "Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ORKA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ORKA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ORKA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.